Today, among metal-based implants, titanium alloy is considered as a suitable option; However, due to factors such as the release of vanadium ions in the body's biological environment, low wear resistance and poor biological properties, bioceramic coatings have been suggested. This research was carried out in two general parts, synthesis of hydroxyapatite particles and coating of prepared particles on Ti6Al4V implant. In the first stage of the research, mesoporous nanostructured hydroxyapatite particles were synthesized by deposition method and characterized by XRD, EDS, FESEM, BET, TEM and FTIR tests. The results showed that elliptical hydroxyapatite particles with a size distribution of 426 nm, consist of self-aggregation of layered nanosheets and with an average porosity size of 14 nm are in the group of mesoporous particles. These particles were then used as carriers in the release of gentamicin in phosphate buffer solution ( with pH = 4.7 and temperature of 37 ° C) and drug release test showed that hydroxyapatite nanoparticles of the prepared mesoporous structure could be To be used as a carrier in controlled drug delivery systems. In the second stage of the research, in order to create better adhesion of the coating, the middle layer of titania was first successfully created by anodic oxidation on Ti6Al4V substrate. Continuation of capacaragnan-hydroxyapatite composite coating with different percentages of 5, 15, 25 and 50% (weight-volume percentage) using sol-gel process and immersion layer on Ti6Al4V alloy substrate in the presence and without the presence of the middle layer Titanium oxide nanotubes were created. Improvement of adhesion to the substrate in the presence of the middle layer was demonstrated by the adhesion test and CaK-25% Hap coating with the middle layer of titania with adhesive strength of 7.42 ± 0.44 MPa recorded the highest adhesion. key words Hydroxyapatite, Mesoporous, Gentamicin, Ti6Al4V alloy, Intermediate layer, Adhesion
